Silo Pharma selects Alphaledger T12 Fund for diversified real-world asset exposure.

Silo Pharma has selected the Alphaledger T12 Fund as a core component of its real-world asset investment strategy on the Solana blockchain. The fund provides diversified exposure to real-world assets and aims to reduce portfolio volatility. This strategic allocation aligns with Silo's objective of generating yield while maintaining a hedge against downside risk.